Search in entities 1
Entities
LogoName Σ Employees
Ikena Oncology Ikena Oncology

Patient-directed oncology therapies across pathways relevant in tumor and immune cells Ikena is a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Our programs focus on key cancer driver pathways that are well-validated in scientific literature but lack approved or effective therapies and therefore have the potential to address high unmet medical needs. By leveraging our deep understanding of discovery chemistry, translational science, and patient-centric drug development, we have built a deep pipeline of wholly owned and partnered programs focused on genetically defined or biomarker-driven cancers, which …

125 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

5 23
ATLANTHERA ATLANTHERA

Bone targeted delivery concept Atlanthera is a drug discovery company focused on bone diseases and bone cancer treatments Our vision: Be the leader in bone-targeted drug delivery to cure bone cancer and metastases Atlanthera can rely on a very high-qualified Team and a worldwide-known experts network Our concept: Bone-targeted delivery of anti-cancer drug www.atlanthera.com Watch our concept in video > https://youtu.be/m3BBWguO6hs Durg discovery, Bone-targeted drug delivery, Bone cancer, and Bone metastases

41 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

2 9
Formation Bio Formation Bio

Bringing new treatments to patients faster and more efficiently. Formation Bio is a tech-driven pharmaceutical company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes critical aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data. The company acquires clinical-stage drugs from pharmaceutical and biotech companies with the goal to develop them faster in order to accelerate access to new treatments for patients, and to unlock greater value per program.

174 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

8 178
Cellomatics Biosciences Ltd Cellomatics Biosciences Ltd

Our expertise, Your discovery Cellomatics Biosciences Ltd. (www.cellomaticsbio.com) is a laboratory-based Contract Research Organisation (CRO) specialised in Oncology/Immuno-Oncology, Immunology/Inflammation and Respiratory therapeutic areas. Based at Colwick Quays Business Park, Nottingham UK, our experienced scientific team offers bespoke and innovative preclinical in vitro bioassay services to support our client’s drug development programmes. We work with diverse group of global clients including early start-ups, virtual/small to medium sized Biotechnology and Pharmaceutical companies. Multiplex Immunoassay, Target and biomarker validation, In vitro functional assays, Molecular Biology, Receptor binding, Toxicity testing, Immuno-Oncology, Oncology, Immunology, Inflammation, and Respiratory

380 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

1 19
Qubit Pharmaceuticals Qubit Pharmaceuticals

Anything is Druggable - with Quantum Accuracy Qubit Pharmaceuticals brings unparalleled accuracy and precision to drug discovery and design, using quantum physics to develop life-changing treatments for major diseases. We leverage our technologies and expertise to advance 7 fully owned drug discovery programs focusing on cancer resistance and escapement, a growing concern in aging populations, and chronic inflammatory diseases. We also co-develop programs with academia and pharmaceutical partners. Our proprietary ATLAS drug discovery platform unites our technologies based on 30 years of research from renowned scientists and founders, Louis Lagardère (Sorbonne University and CNRS), Matthieu Montes (CNAM), Jean-Philip Piquemal (Sorbonne …

67 similar entities Tags: FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

68 71
Icosagen Icosagen

European Mammalian CRDMO - From Discovery mgs to Clinical GMP kgs. Icosagen is a unique European CRDMO, being successfully in the business for more than 25 years as an independent family-owned company. As such, we combine pre-clinical CRO and clinical CDMO development expertise at one single site for therapeutic antibodies, multispecifics, ADCs, and other complex recombinant protein drug candidates. As a CRDMO we discover, develop, and manufacture proteins seamlessly from research concepts into pre-clinical and clinical development stages. This includes everything from small-scale transient productions to stable high producing cell lines, to manufacture clinical GMP materials in our modern 200/1000L …

135 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

2 148
MSD Italia MSD Italia

We have always invented for one and great purpose: life We have always invented for a single great purpose: life MSD, known in the United States and Canada with the name of Merck & Amp; Co., Inc., with headquarters in Kenilworth, (New Jersey, USA), is an American multinational leader in the pharmaceutical sector. For over 65 years in Italy and 130 in the world, we have revolutionized the therapeutic paradigms for dozens of pathologies through the discovery of over 200 innovative molecules. Our mission is to discover, develop, make innovative products and services available that save and improve the lives …

35 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

12 628
Dragonfly Therapeutics, Inc. Dragonfly Therapeutics, Inc.

Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel multispecific antibody technology to harness the body's immune system to bring breakthrough treatments to patients. In addition to its wholly owned clinical assets, Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platform, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas. For more information, email info@dragonflytx.com. immuno-oncology

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

4 98
Skyhawk Therapeutics Skyhawk Therapeutics

We Use Small Molecules To Modify RNA Splicing Skyhawk Therapeutics is a drug discovery and development company focused on revolutionizing disease treatment with small molecules that modify RNA expression. Our founders are leading experts in small molecule therapeutics development for RNA-based disease. Our first drug candidates are targeted toward cancers and neurological conditions. The company is based in Waltham, Massachusetts. For more information, please visit: www.skyhawktx.com.

71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

3 66
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

A Member of the Roche Group Poseida was acquired by Roche in early 2025 and is now part of the Roche Group. Poseida is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral DNA Delivery System, Cas-CLOVERTM Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Genome Engineering, CAR-T cells, Gene Therapy, Gene Editing, Cell Therapy, Adoptive Cell Therapy, Multiple Myeloma, Prostate Cancer, Transposon, Non-viral, Biotechnology, Immunotherapy, Regenerative …

76 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

3 234
Abzena Abzena

Abzena is the leading end-to-end bioconjugate & complex biologics CDMO+CRO, focused on rapidly moving medicines forward. Abzena is the leading end-to-end bioconjugate, ADC, and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule and move medicines forward faster. The company has research, …

74 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

7 431
Voyager Therapeutics, Inc. Voyager Therapeutics, Inc.

Leveraging genetics to treat neurological diseases Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACERTM AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

3 179
InCarda Therapeutics InCarda Therapeutics

Pioneering inhaled medications for cardiovascular conditions InCarda Therapeutics is a clinical stage drug delivery company pioneering a novel approach of treating cardiovascular diseases and conditions by the inhalation route. The lead product under development is an inhaled therapy to treat a common atrial arrhythmia, paroxysmal atrial fibrillation (PAF). Cardiovascular, Inhalation therapy, Biotechnology, Pharmaceuticals, Clinical Development, Drug Formulation, Commercialization, Clinical Research, Pre-Clinical Research, and Regulatory Affairs

86 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

1 15
TG Therapeutics, Inc. TG Therapeutics, Inc.

TG is a biopharmaceutical company focused on the development of novel treatments for B-cell diseases. TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS). Biotechnology, hematological malignancies, non-Hodgkin's lymphoma, multiple sclerosis, b-cell diseases, ublituximab, and umbralisib

65 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

0 436
Sinnovial SAS Sinnovial SAS

SINTOTEST® supports rheumatologists in optimizing the prescription of rheumatology biotherapies Sinnovial is a biotechnology company that develops personalized medicine devices to improve the management of chronic inflammatory rheumatism (RIC) in rheumatology (rheumatoid arthritis, ankylosing spondylarthritis, in particular). Our mission: to improve the quality of life of patients by maximizing the chances of success of their biotherapy treatment. Our goal: to provide the doctor with a therapeutic orientation assistance system that allows him, in real time, to optimize the selection of biotherapy. "The right treatment, at the right patient, at the right time!" »» Biotechnology, rheumatology, medtech, and chronic inflammatory rheumatism

33 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

4 3
Medannex Ltd Medannex Ltd

Award-winning Scottish biopharmaceutical company, advancing the treatment of cancers and autoimmune diseases. Medannex is an award-winning Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1. Our goal is to create a first-in-class therapy to improve the lives of people impacted by cancers and autoimmune diseases. Following a recent Series B fundraise, and supported by both the Scottish Investment Bank and Innovate UK, Medannex is collaborating with world-leading clinical experts to explore the huge therapeutic and commercial potential of our patent-protected immunomodulatory technology. Antibody development, Innovation, Biotechnology, T cell modulation, Skills development, Autoimmune diseases, Inflammation, Lupus, SLE, Collaboration, …

74 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

3 12
PK MED PK MED

Tailor-designed drug implants ​for local treatments. Founded by Truffle Capital. PK MED is a pioneering French biotech company, privately owned and founded in 2019 in Lyon, France, with the backing of Truffle Capital, a leading European venture capital firm specializing in life sciences. Built around a dedicated team of passionate and seasoned experts in pharmaceutical sciences, drug delivery, and biomaterials design, PK MED combines innovation and expertise to develop cutting-edge solutions in healthcare. PK MED specializes in the development of innovative, custom-designed, injectable, and biodegradable micro-implants, leveraging its expertise to address critical healthcare challenges. Our focus lies in advanced drug …

7 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

7 11
SciRhom SciRhom

Targeting iRhom2 for better treatment of autoimmune diseases SciRhom GmbH, based in IZB Martinsried, Germany, is a biotech start-up company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening diseases. Founded in late 2016, we develop first-in-class antibodies against iRhom2, a key modulator of several crucial pro-inflammatory signalling pathways, including TNF-alpha signalling. Following the preclinical and early clinical development of these monoclonal antibodies, we are aiming to provide superior treatment options to currently existing inhibitors of TNF-alpha signaling. SciRhom is poised to transform the lives of patients with autoimmune diseases. drug …

27 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

3 19
PartitionBio Ltd PartitionBio Ltd

Exploiting a proprietary tech platform to develop biomolecular tools for therapeutic & synthetic biology applications PartitionBio Exploiting a novel proprietary technology platform to develop biomolecular tools for the use in therapeutic and synthetic biology applications. contact@partitionbio.co.uk

326 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

0 12
Calico Biosystems Calico Biosystems

Predicting life-changing drugs for patients with cancer Calico Biosystems is on a mission to help pharma companies create effective, affordable drugs faster to counter cancer multi-omics assay, computational modeling, drug efficacy prediction, combination therapy, and Cell and virus-based therapeutics' efficacy

542 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

2 2
Ethris Ethris

Clinical stage biotech company focused on development of disruptive mRNA therapeutics for severe respiratory diseases Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients’ cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners. Biotechnology, mRNA, LNPs, Vaccines, Therapeutics, Formulation, and Manufacturing

71 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

0 47
Overseed Overseed

Medical cannabis: from seed to purified pharmaceutical grade active ingredients Overseed is the first French biotech company to obtain its license from the ANSM to start its R&D process on cannabis production for pharmaceutical purposes. We are a Biotech which combines leading expertise in genetics, agronomy, organic chemistry and pharma with the ambition to have an expert knowledge on the production of therapeutic cannabis. We will produce GACP and GMP certified dried flowers, full spectrum extracts and purified pharmaceutical grade active ingredients for laboratories. Overseed's research and experimentation will answer patients and the health industry expectations to guarantee production sovereignty, …

53 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

3 24
SmartCella Holding AB SmartCella Holding AB

A global biotech company pioneering the future of targeted medicines SmartCella is a global biotech company pioneering the future of targeted therapies through delivery solutions and advanced therapy development. Founded in 2014, the company is built on globally renowned science and research from Karolinska Institutet in Sweden. SmartCella combines novel delivery platforms, such as the Extroducer® (an endovascular delivery device that enables direct injection to hard-to-reach organs and tumors), with state-of-the-art development and manufacturing of stem cell-based therapies. The company operates in two business segments: Targeted Delivery and Regenerative Medicines. The international team consists of scientists, visionary innovators, and experienced …

63 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

0 64
Atoxigen Atoxigen

ATOXIGEN is your partner in early R&D. We offer a variety of standardized or customized assays based on the latest innovations in the fields of cellular biology, molecular biology and genomics. Innovative predictive efficacy assays on reconstructed epidermis or primary cell lines from human explants (proteasome, autophagy, detoxification, anti-ageing...); in vitro genotoxicity testing (micronucleus and chromosome aberration tests); endocrine disruptor screening; customized services. Biotechnologies, Testing & Research, Evaluation toxicologique, and Assurance qualité

89 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

2 3
Acceleron Pharma Acceleron Pharma

Accelerating drug discovery to transform patients' lives Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com Biopharmaceuticals, Orphan Disease Therapeutics, Rare Diseases, and Serious Diseases

610 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

6 67
Sonata Therapeutics Sonata Therapeutics

Sonata Therapeutics is a new, Boston-based Flagship Pioneering company revolutionizing the world’s understanding of the cellular microenvironment and its importance to human biology and disease. Our product-platform creates drugs based on a systematic, comprehensive characterization of the microenvironment in diseases with high unmet medical need. Through our pioneering science, we identify new targets for therapeutics that induce the release of a programmed diversity of signals with the potential for significant patient impact. Our employees are exceptionally passionate, accountable, collaborative, and innovative. Sonata Therapeutics was founded by Flagship Pioneering, an organization dedicated to the origination and development of first-in-category life sciences …

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

7 20
OxSonics Therapeutics OxSonics Therapeutics

Tackling the toughest cancers. We’re OxSonics, a pioneering clinical-stage therapeutics company committed to developing a ground-breaking platform technology to make anti-cancer drugs smarter, act faster and, above all, work better. Our SonoTran® Platform has been designed to actively enhance the delivery of oncology drugs into solid tumours. SonoTran® is drug agnostic and requires no drug reformulation enabling its use with both existing and novel therapies. We have our own development programs as well as collaborations with Pharmaceutical and biotech companies to work to bring smarter, faster and better therapies to as many patient groups as possible. Drug Delivery, Oncology, Medical …

80 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

2 14
OMass Therapeutics OMass Therapeutics

OMass Therapeutics is a private pharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. OMass is backed by Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures and British Patient Capital.

55 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

14 85
Shorla Oncology Shorla Oncology

At Shorla Oncology we develop and commercialize innovative oncology medicines for women’s and pediatric cancers. At Shorla Oncology we develop and commercialize innovative oncology drugs. We focus on indications where existing treatments are limited, in shortage or inadequate for the target population. Our products are the result of Shorla’s world class team encompassing thought leaders, clinicians, scientists and commercial strategists who have extensive experience in the area of drug development and commercialization of niche cancer treatments. Our growing portfolio will bring accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care and providing a significant clinical …

33 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

8 50
SYNAXYS SYNAXYS

Accelerate drug development for neurological diseases SYNAXYS is French biotech specialized in the characterization of the response of the nervous system for nutraceutic, pharmaceutic and veterinary applications. We offer a complete range of R&D services to support drug development, from defining the dose effects in a human model, to identify biological targets and action mechanism, acute and chronic toxicity, or comparison to established treatments. Our field of application: - Drug positioning - Therapeutic evaluation in a diease model - Neuro-oncology - Data generation for IA modeling Neuro-engineering, Neuronal diseases modeling, Neuro-oncology, Autism, Alzheimer disease, and Glioblastoma

100 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

3 2
4P-Pharma 4P-Pharma

Transforming science into drug success stories Established in 2014, 4P-Pharma is a clinical-stage biotech company dedicated to addressing serious diseases with significant unmet medical needs. Our goal is to bring first-in-class therapies to patients swiftly.​ Our core is a specialized R&D engine that enhances risk management and accelerates the development process, effectively cutting down on time, costs, and uncertainty.​ We focus on developing assets combining rapid time to market and solid intellectual property. Our strategy leverages cutting-edge clinical trial designs and expedited regulatory pathways to bring our therapies to those in need as quickly as possible. Translational research, Biotechnology, Pharmaceuticals, …

167 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

31 30
SYNSIGHT SYNSIGHT

Synsight activity is now integrated into @iktos https://iktos.ai/ https://www.linkedin.com/company/iktos/ Synsight was a company created in 2013, by two co-founders PhD Computer aided drug design: Cyril Bauvais (CEO) and Guillaume Bollot (CSO). In july 2024, Synsight was acquired by @iktos, an AI drug discovery company. Its tech is based on AI drug design and cell imaging, including a proprietary cell based assay named MTBench, to profile compounds modulators of protein-protein and protein-RNA interactions, and protein agregation. criblage virtuel, modélisation moléculaire, dynamique moléculaire, QSAR, drug design, chémoinformatique, and drug discovery

65 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

12 1
Domain Therapeutics Domain Therapeutics

#biopharma #biotech #drugdiscovery #GPCR #Immunooncology #inflammation Domain Therapeutics, a clinical-stage global biopharmaceutical company, focused on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Two decades of solid experience in GPCR drug discovery, validated by multiple pharma partnerships, associated to a target identification and drug discovery platform enable the Company to enhance the understanding of cancer and …

24 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

25 80
Valerio Therapeutics Valerio Therapeutics

Valerio is a clinical-stage biotechnology company developing novel oncology drugs targeting tumor DNA-binding functions. Valerio Therapeutics is a clinical-stage biotechnology company based in France and the US that develops new drugs by targeting tumor DNA functions through unique mechanisms of action in the field of DNA Damage Response (DDR). DDR consists of a network of cellular pathways that detect, report and repair DNA damage. Applied to oncology, this new field of research aims to weaken or block the ability of tumor cells to repair damage to their DNA, either naturally or under the effect of cytotoxic treatments. Focusing exclusively on …

25 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

1 48
MolDrug MolDrug

Chemoinformatics and modeling solutions to optimize your drug candidates. MolDrug (a ProtoQSAR company) is a group specializing in the design and optimization of molecules through Machine Learning-powered chemoinformatics and structural bioinformatics. Our models allow for the prediction of molecular properties (QSAR) and detailed interaction analyses (molecular modelling). We work with all types of compounds, including small molecules, peptides, nanomaterials, mixtures... Our tools allow for the prediction and assessment of physicochemical, biological, pharmacological, and/or (eco)toxicological properties of substances with an array of advantages: - faster results - saving money and resources - reduce animal testing (3 Rs) - regulatory validity (REACH, …

58 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

0 4
Bioceltix Bioceltix

Bioceltix is changing the veterinary therapy standards. We develop innovative biopharmaceuticals based on stem cells. Bioceltix is a biotech start-up which deals with the development of stem cell-based medicinal products for veterinary use. Currently, our main goal is to implement a biopharmaceuticals based on allogenic stem cells. The medicines will be primarily to serve the treatment of accompanying animals. The new product candidates will become a milestone in the field of stem cell-based biopharmaceuticals for veterinary use. As one of the first such Europe-based company, Bioceltix product intends to go through the full registration path to a marketed drugs devised …

57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

4 34
Carcinotech Carcinotech

Advancing Cancer Treatment Breakthroughs Carcinotech provides comprehensive solid tumor research services to advance drug development and enhance personalized therapy decisions. At the heart of its offerings is the proprietary Carcino3DTM bioprinting technology, which creates assay-ready, 3D tumors derived from patient biopsies. This innovative, translational approach delivers a predictive in vitro model, generating critical insights into therapeutic efficacy, and treatment optimization. Cancer research, 3D bioprinting , Cancer microenvironment, drug testing, oncology, assay services, oncology pre-clinical services, solid tumours, solid tumors, tumour microenvironment, tumor microenvironment, early phase drug development, and early drug discovery

170 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

2 19
AFFIRMA BIOTECH SL AFFIRMA BIOTECH SL

Affirma Biotech develops new products to overcome the challenge of Multi Drug Resistant and Chronic Infections Affirma Biotech is a start-up company specialized in the discovery and development of new anti-infective drugs via immunomodulation.

437 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

0 5
Infinitopes Infinitopes

Preventing deaths from cancer metastases Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-led biotech spinout from Oxford University, we are empowering the immune system to fight cancer metastases with unique, de novo antigen discovery technologies, innovative high efficiency vectors and intelligent clinical trial design. Our mission is to significantly enhance patient survival.

293 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

5 35
Hemispherian AS Hemispherian AS

Hemispherian is a biotechnology company developing new treatments for the most aggressive types of cancer. Hemispherian is a biotechnology company developing new treatments for the most aggressive types of cancer. Our mission is to develop a new drug to treat Glioblastoma Multiforme. We aim to significantly increase life expectancy for patients, improve patient comfort, and generally increase the overall survival rates for GBM patients. cancer treatments, GBM treatments, and therapeutics

58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

2 10
SCYNEXIS, Inc. SCYNEXIS, Inc.

Committed to protecting the world against dangerous and difficult-to-treat fungal pathogens At SCYNEXIS, we are bringing a ground-breaking class of drugs to the battle by developing innovative products that have the strength, safety, and versatility to defeat even the most insidious fungal diseases. We are committed to positively impacting the lives of patients suffering from fungal infections — from the most common to the difficult-to-treat and deadliest. (NASDAQ: SCYX) The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. Antifungals, Drug Development, Biotech, Infectious Disease, and …

61 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

3 54
AdipoPharma SAS AdipoPharma SAS

French biotech company targeting the Adipocyte to treat insulin resistance, type 2 diabetes and associated comorbidities AdipoPharma is a French biotech company with a US subsidiary committed to understanding the role of the adipocyte cells in diabetes via their unique effect on lipid biosynthesis and management of whole-body lipid homeostasis. Our first-in-class candidate - PATAS - is set to enter clinical trials later this year.

72 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

23 6
BiPER Therapeutics BiPER Therapeutics

First in class small molecules pushing cancer cells to burn out BiPER Therapeutics is developing a first-in-class pipeline of therapeutics overstressing cells to cure patients. The company’s lead compound, BPR001, is a first-in-class small molecule therapeutic targeting BiP, an oncogenic protein shown to have a critical role in cancer

58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

13 8
OSE Immunotherapeutics OSE Immunotherapeutics

Immuno-Oncology and Immuno-Inflammation - Breakthrough Immuno-Science for Patients OSE Immunotherapeutics, a biotech dedicated to developing first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). • Tedopi® (therapeutic cancer vaccine): Registration Phase 3 in 2nd-line NSCLC in HLA-A2+ patients with secondary resistance. Phase 2 trials, sponsored by onco groups, of Tedopi® in combo in solid tumors. • Lusvertikimab (mAb IL-7R antagonist); Positive Phase 2 in UC; preclinical research in ALL. • OSE-279 (anti-PD1): 1st positive results in Phase 1/2 in solid tumors. • FR-104/VEL-101 (anti-CD28 mAb): developed in partnership with Veloxis in transplant; Phase 1/2 in renal transplant (CHU Nantes); successful Phase …

57 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

27 1
ORPHELIA Pharma ORPHELIA Pharma

Children with rare diseases deserve therapeutic answers ORPHELIA Pharma is a French pharmaceutical company based in Paris and Lyon that develops and markets medicines for the treatment of pediatric orphan diseases. ORPHELIA Pharma‘s mission is to provide patients with essential products in the fields of epilepsy and pediatric oncology, with formulations adapted to the pediatric population. With one drug approved in the European Union and one product in late-stage clinical development, ORPHELIA Pharma has recently established regional agreements in the European Union, the USA and China and conducts research projects through academic and industrial partnerships. Neurology, Pediatry, Orphan drug, and …

16 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

1 11
ANTINEO ANTINEO

Antineo aims to accompany customers in the preclinical development of novel anticancer agents. We provide services and strategic advice for preclinical development, optimal choice of in vitro and in vivo models as well as strategic input on potential indications to target in the therapeutic landscape. Développement préclinique, in vitro, ex vivo, in vivo, Preuve de concept, Expertise scientifique en pharmacologie, and Modèles à façon

143 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

6 9
BioPharmAnalyses BioPharmAnalyses

Biopharmalysis is an information site that allows you to make an active watch and follow the strategic developments of companies in the biopharmaceutical sector. With biopharmalysis: • You get a synthetic view of recent news from the sector • You are aware of the latest key agreements and mergers and acquisitions • You follow the clinical and regulatory progress of development products • You have access to the latest subsidies, fundraising and IPOs on the stock market Its five databases have more than 13,000 interactive sheets on agreements, clinical trials, fundraising, mergers/acquisitions and the regulatory life of biopharmaceutical products in …

30 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

16 2
Medivir AB Medivir AB

Improving life for cancer patients through transformative drugs Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a smart, targeted chemotherapy designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share …

61 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

1 47
Ousia Pharma Ousia Pharma

Danish biotech company developing peptide-small molecule drugs for treatment of obesity Ousia Pharma is a biotech spin-out from the University of Copenhagen developing novel peptide-drug conjugates for treatment of obesity and metabolic diseases. The company uses a proprietary targeting approach in which peptides are used to deliver modulators of synaptic plasticity to drive a potent and sustained weight loss without compromising safety. A main objective of Ousia Pharma is to advance the development of the lead weight loss drug candidate (OP-56) within general obesity.

17 similar entities Type: Startup Activities: healthtech Technologies: Synthetic Biology

0 8
Nimbus Therapeutics Nimbus Therapeutics

We develop breakthrough medicines for patients through precision small molecule design. Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company developing novel small molecule medicines designed to act against well-validated but difficult-to-drug targets implicated in multiple human diseases. The company advances promising research based on a unique strategy that combines leading-edge computational technologies with a tailored array of machine learning-based predictive modeling approaches. Nimbus' pipeline includes a clinical-stage HPK1 inhibitor for the treatment of cancer (NCT05128487), as well as a diverse portfolio of preclinical programs focused on cancer, including a WRN program for MSI-H cancers, autoimmune conditions, and metabolic diseases. …

56 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

10 110
Op2Lysis Op2Lysis

A New Hope for Hemorrhagic Stroke Op2Lysis develops new treatments for patients suffering from thrombosis at the cerebrovascular level, with an initial focus on the hemorrhagic form of stroke. Indeed, there is no currently approved and available therapeutic solution for these patients. The company develops its game-changing NANOp2Lysis platform, associating a breakthrough vectorisation technology, industrial know-how enabling clinical quality production, and preclinical expertise to propose predictive and translational models, a first in this field. O2L-001, the first product resulting from this technology, will soon enter regulatory toxicology with the aim of applying for clinical trial authorisation in patients in North …

33 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

6 8
Pomega Laboratories Pomega Laboratories

New Natural & Ethical Anti Inflammatory Pharmaceutical Products Natural Products with Proven Health Claims For PETS. Pomega develops a novel, safe, ethical and non-toxic therapy that retards disease progression by inhibiting cartilage breakdown at an earlier stage. Product is developed by skilled pharmacist under drug standards frame First product coming out the pipeline is Ω-344 Product , a patented fruit extract with strong anti inflammatory properties osteoarthritis , anti inflammatory, fruit extract, inflammation, arthritis, biotech, NSAIDs, pain, animal, dogs, pets, wellness, healthcare, petfood, and cats

13 similar entities Type: Startup Activities: pettech deeptech biotech Technologies: Synthetic Biology

1 1
Advesya Advesya

Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

402 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

11 10
Genvade Therapeutics Genvade Therapeutics

Dedicated to developing treatments for rare diseases originated from nonsense mutations Genvade aims to harness the power of nonsense mutation readthrough molecules to develop treatments for some of the most burdensome rare diseases. Our lead compound targets indications include cystic fibrosis, Duchenne muscular dystrophy and other genetic diseases. small molecules, drug discovery and development, rare diseases, nonsense mutation corrector, cystic fibrosis, genetic diseases, oncology, readthrough, and Duchenne

100 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

2 N/A
Cellarity Cellarity

Rewriting the rules of drug creation Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas …

281 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

4 96
MyoKardia MyoKardia

Driven by the heart We officially combined with Bristol Myers Squibb to further strengthen our scientific capabilities and treatments for cardiovascular patients. Visit www.bms.com to learn more about our work to produce the next generation of medicines for patients with serious cardiovascular disease. For more information on the acquisition, see our press release at: https://one.bms.com/40FsT7W Genetic Heart Disease, Cardiomyopathy, biotechnology, cardiovascular disease, heart failure, precision medicine, therapeutics, drug discovery, drug development, and R&D

Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

1 29
Mersana Therapeutics Mersana Therapeutics

Our mission is to discover and develop life-changing antibody-drug conjugates (ADCs) for patients fighting cancer. At Mersana, we have a passion for advancing therapies to make a significant impact in the lives of people living with cancer. Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline …

38 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

4 136
Array BioPharma Inc. Array BioPharma Inc.

Array BioPharma Inc. (NASDAQ: ARRY) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Eight registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics). We have locations in Boulder, CO; Cambridge, MA; and Morrisville, NC. Small molecule drug discovery and development., oncology, biotechnology, melanoma, and colorectal cancer

77 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

2 111
RoslinCT RoslinCT

Your Advanced Cell & Gene Therapy CDMO Partner RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the groundbreaking technology cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones, including being among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR-edited stem cell-based therapy for a major disease to …

63 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

4 423
Cogentis Therapeutics, Inc. Cogentis Therapeutics, Inc.

Developing first in class therapies for the treatment of dementia. Cogentis Therapeutics is an early stage biotechnology company with a mission to develop and commercialize an innovative disease-modifying therapeutic for dementias such as frontotemporal dementia (FTD) and Alzheimer’s disease (AD) to improve patients’ quality of life and reduce the burden of disease on their families, providers, and the overall healthcare system. Our immediate goal is to develop a peptide-based compound, CT-526, for FTD. neurodegeneration, neuropeptide, frontotemporal dementia, Alzheimer's disease, and progressive supranuclear palsy

32 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

1 7
VRG Therapeutics VRG Therapeutics

Regional leader in preclinical R&D with a world-class protein evolution tech platform for CGT applications Our mission is to cure diseases via targets and MoAs that cannot be reached with traditional approaches. Leveraging our unique platform, we optimize peptides/proteins of natural origin using directed evolution to create cutting-edge CGT products or peptide-based pharmaceuticals. VRGT’s management and staff members were selected based on their international research experience and outstanding pharma industry achievements. Our people have outstanding professional expertise in preclinical/clinical R&D and scientific project management, pharmacology, business development and medical marketing. For years, they have worked in the most prestigious academic …

155 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

1 27
Venatorx Pharmaceuticals, Inc. Venatorx Pharmaceuticals, Inc.

Discovering & developing novel anti-infectives to treat multi-drug resistant bacterial & hard-to-treat viral infections. Venatorx Pharmaceuticals is a private pharmaceutical company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. antibiotics, antiinfectives, antivirals, drug development, drug discovery, pharmaceuticals, #battlesuperbugs, #WorkingToFightAMR, clinical, research, #squashsuperbugs, biotech, and antimicrobialresistance

78 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

0 58
mYXpression mYXpression

Digital bio-solutions designed to support the development of biomedicines and optimize their prescription. mYXpression is an innovative French company positioned in the field of health innovation. The company, specialized in R&D, develops innovative tools to assist in the prescription of biomedicines. Its first tool, the RITI® RA test, provides a personalized report specific to the patient by indicating an efficacy score for each biotherapy. This brand new approach provides numerous useful insights to the doctor by assisting in the prescription of biotherapy in order to increase the patient's chances of remission. bio-numérique, innovation technologique, big data, bio-technologie , biotherapie, intelligence …

57 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: A.I.

22 5
Molecular Templates Molecular Templates

Engineering the Next Generation of Therapeutics Molecular Templates, Inc. (MTEM) is a clinical stage biopharmaceutical company focused on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform with unique mechanisms of actions which are highly differentiated from antibody drug conjugates (ADCs). MTEM is developing MT-6402, which is in a Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients; MT-5111, which is in a Phase I clinical trial for the treatment of HER2-positive cancers; and MT-0169, …

39 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

1 34
C4 Therapeutics, Inc. C4 Therapeutics, Inc.

Clinical-stage biotech company transforming how disease is treated through targeted protein degradation science C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve …

58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

7 125
AdhexPharma AdhexPharma

We deliver solutions AdhexPharma is an independent drug delivery company specialized in Transdermal & Topical patches and Oral Thin Films technologies. AdhexPharma is based in France, with GMP manufacturing facility for European and US market. We have 4 approved products in Europe and North America and a pipeline of 6 candidates, ranging from 505(b)2 / NDA and ANDA in different therapeutical areas: pain, CNS, anesthesia, smoking cessation and HRT. Trandermal, Patch, Oral Thin Film, Drug Development, GMP manufacturing, FDA approved, OTF, ODF, cGMP, TDS, CDMO, and CMO

62 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

16 149
Debiopharm Debiopharm

we develop for patients Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe. Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections. Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat® If your university …

76 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

16 478
Selvita Selvita

Integrated Drug Discovery | Drug Development | Contract Research Selvita is one of the largest preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development. biotechnology, pharmaceuticals, drug discovery, preclinical research, bioanalytical development services, bioinformatics, systems biology, proteins, genomics, proteomics, autoimmune disorders, regulatory studies, medicinal chemistry, agrochemical, industrial chemistry, and assay development&screening

504 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

4 784
Cytokinetics Cytokinetics

Empowering Muscle Empowering Lives Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Proud to be a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022 and a part of Fortune's Best Workplaces in the Bay Area in …

60 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

7 618
NGM Biopharmaceuticals NGM Biopharmaceuticals

Explorers on the frontier of life-changing science. NGM Bio is a biopharmaceutical company focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. The company’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. All therapeutic candidates …

53 similar entities Type: Startup Activities: biotech manufacturing deeptech Technologies: Synthetic Biology

2 118
Evexta Bio Evexta Bio

Evexta Bio, formerly #Diaccurate, is a biopharmaceutical company exploring the new frontiers of #oncology in search of daring novel therapeutic approaches with the potential to save lives. Now in the clinic, the French biotech is currently developing two proprietary therapeutic assets with novel mechanisms of action across several indications: - Rupitasertib, formerly DIACC3010, an optimized S6K inhibitor with efficient AKT1/AKT3 control of feed-back loop. The oral anti-tumor agent is expected to enter phase 2/3 clinical trial in refractory ER+ HER2- metastatic breast cancer. - EVX020, formerly DIACC2020, an antibody-drug conjugate program using a sole-in-class KIF20A kinesin inhibitor as payload in …

74 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

6 10
Inventiva Pharma Inventiva Pharma

A clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies. Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology. Our research and development programs target indications with substantial unmet medical needs: NASH, MPS and oncology. Drug Discovery, Biotech, Oncology, Fibrosis, Lysosomal Storage Disorders, NASH, and SSc

154 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

5 122
SFL is now Veristat SFL is now Veristat

Solutions For Life sciences SFL, a Veristat company - Integrated Solutions for Healthcare Products SFL is a leading consultancy providing integrated solutions to pharma, biotech and medtech companies for all product life cycle stages: Regulatory Affairs & Regulatory Intelligence, Quality & Supply Chain, Medical Writing, Public Affairs & Market Access, Pharmacovigilance, and Healthcare Compliance. In addition, SFL can act as marketing authorization applicant and MAH in Switzerland and the EU and conduct submissions to FDA, PMDA and Health Canada and other authorities. As a Veristat company, SFL clients also have access to a substantial range of clinical development services such …

48 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

10 362
KCAS Bio KCAS Bio

A contract research organization (CRO) advancing the latest in drug development with leading sponsors, worldwide. KCAS Bio is a top-tier contract research organization (CRO) that has 45 years of experience with both large pharma and biotech sponsors, providing comprehensive bioanalytical drug development services from early discovery through registration. We have supported more than 300+ FDA approved drugs on the market, developed 5,000+ proprietary and non-proprietary assays to date, and undergone 18 FDA audits with no major findings. Our presence in multiple locations throughout the US and Europe - and with a strategic alliance in Australia - allows us to serve …

140 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

7 372
Poolbeg Pharma plc Poolbeg Pharma plc

Clinical-stage biopharma company focussed on the development of innovative medicines to address unmet medical need Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs. The Company’s clinical programmes target large addressable markets including, cancer immunotherapy-induced Cytokine Release Syndrome (“CRS”) and metabolic conditions such as obesity with the development of an oral encapsulated glucagon-like peptide GLP-1R agonist. Ticker AIM: POLB cancer immunotherapy, oncology, GLP-1 agonist, obesity, RSV, influenza, Oral GLP-1, metabolic conditions, Artificial Intelligence, and AI

65 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology A.I.

9 15
Pharvaris Pharvaris

Pioneering science for patient choice Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically …

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

0 124
STANIPHARM STANIPHARM

Expert services in supercritical CO2 and nanomedicines for the life science industry StaniPharm is a Contract Development and Manufacturing Organization (CDMO). Pioneers in supercritical CO2 technologies, we operate a state-of-the-art facility and provide the life science industry with flexible development and GMP manufacturing services. We move your products from idea to market: botanical extracts, challenging polymers and lipids, nanomedicines, tailored drug particles. Keywords : nanoparticles, medicinal cannabis, particle and crystal engineering, crystallization, polymers, lipids, supercritical fluids, purification, formulation, impregnation, sterilization, GMP manufacturing, poorly soluble drugs, polymorphism, CDMO drug delivery, supercritical fluids, formulation, nanoparticles, GMP manufacturing, poorly soluble drugs, sterilization, impregnation, …

17 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

2 14
Leads To Development Leads To Development

An expert team helping biotechs bring their drugs to and through clinical trials as efficiently as possible. Your expert team from concept to clinic. At Leads to Development, we use our knowledge and expertise to help biotechs bring their drugs to and through clinical trials as efficiently as possible, delivering value for companies and life-changing outcomes for patients. With decades of experience, more than 180 projects under our belt throughout Europe and the US, and a 100% success rate in obtaining clinic trial authorisations, our team provides comprehensive end-to-end support across all areas of new drug development. Our backgrounds are …

107 similar entities Type: SMB Startup Activities: biotech deeptech Technologies: Synthetic Biology

7 18
Sygnature Discovery Sygnature Discovery

#EnablingSuccess Sygnature Discovery is a world-leading integrated drug discovery contract research organization based in the UK and Canada with headquarters in Nottingham (UK). Additional sites are located in Alderley Park, Macclesfield, and Glasgow (UK), as well as Montreal and Quebec City (Canada). Its team of over 1,000 employees, which includes 900 scientists, partners with global biotech, pharma and NFP organizations. Since 2011, Sygnature Discovery has delivered 50 novel pre-clinical and 30 clinical compounds, with its scientists named on over 170 patents. Therapeutic areas of expertise include oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases, and more. Founded …

75 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

15 670
Frontage Laboratories, Inc Frontage Laboratories, Inc

Accelerare le scoperte, trasformare la vita! Frontage Laboratories is a US-based Contract Research Organization (CRO) that was initially established in New Jersey in April 2001 and later relocated to Pennsylvania in 2004. As an FDA-registered and inspected global pharmaceutical development and manufacturing organization, Frontage is headquartered in Exton, PA, with an impressive network of 26 facilities spread across Pennsylvania, New Jersey, Illinois, Ohio, California, Florida, Canada, Italy, and China. We are dedicated to accelerating the development of innovative therapies by providing a broad range of science-driven and quality-focused services including drug discovery, DMPK, preclinical safety & toxicology, formulation development and …

105 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

1 684
AB Science AB Science

AB Science was founded in 2001 by a team of researchers, clinicians and entrepreneurs who have dedicated their lives to discover key mechanisms in life science and develop new drugs targeting these mechanisms to dramatically change the life of patients in the most unmet medical needs. We are innovators and scientific entrepreneurs in the field of life science. Our group is specialized in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical needs in the field of cancers, chronic inflammatory diseases and neurological degenerative disorders. Our pipeline is both in Human and Veterinary medicine. Our drugs are …

95 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

3 15
Algonist Biotechnologies Algonist Biotechnologies

Targeting Chronic Pain Algonist Biotechnologies is a pre-clinical stage biotechnology company, developing novel small molecule therapeutics for chronic pain. Our mission is to develop drugs with similar potency to opioids but without leading to addiction.

82 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

0 2
Bioxis Pharmaceuticals Bioxis Pharmaceuticals

#BeyondInnovation #DermalFiller #CYTOSIAL #AestheticMedicine New ideas, new innovations, new ways of thinking for the medical device industry. We are a pharmaceutical company specialized in the discovery, clinical development, production and commercialization of innovative products in the field of regenerative medicine. At Bioxis Pharmaceuticals, we contribute to transform science into groundbreaking medical device that meet doctors need to improve the health and well-being of their patients in the field of dermatology and aesthetic medicine. Medical Device, Dermatology, Aesthetic, Cosmetic surgery, Regenerative medicine, Ultra-pure chitosan, and Hyaluronic Acid

303 similar entities Type: Startup Activities: healthtech manufacturing deeptech biotech Technologies: Synthetic Biology

5 28
Coral Biome PHARMA Coral Biome PHARMA

CORAL BIOME PHARMA Live cultured corals for Drug discovery Coral Biome is a research and development company dedicated to the discovery of marine natural products of interest for major public health issues such as cancer, inflammation and multi-drug resistant infectious diseases. Our multidisciplinary team of research and worldwide network of collaborators gathers a unique set of competitive expertise including, aquaculture, marine biology, chemistry, cell biology and cancerology to successfully isolate marine natural products and test their biological activity. We maintain a large-scale untapped reservoir of coral species to preserve endangered species, sell corals for aquarium trade (http://www.coralbiome.com/aquaculture/) and provide research …

23 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

1 1
Rahko Rahko

Part of Odyssey Therapeutics Rahko was acquired by Odyssey Therapeutics in 2021. Odyssey Therapeutics is a biotech company pioneering next gen immunomodulators and oncology medicine. Read more: https://odysseytx.com/news/

73 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

5 1
Alesta Therapeutics Alesta Therapeutics

Oral small molecules for rare diseases Alesta Therapeutics is a pioneering company based in Leiden, Netherlands, dedicated to the development of first-in-class small molecules that target GCN2. Our commitment to advanced, high-quality chemistry has led us to develop a clinical candidate with an extensive pre-GLP toxicology and CMC package.

137 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

0 10
Keltic Pharma Therapeutics Keltic Pharma Therapeutics

The KELTICPharma team combine academic innovation, deep target knowledge and corporate drug discovery expertise. In 2019 Prof Andrew Tobin published validation of PfCLK3 as a target with breakthrough potential in the treatment of malaria. Successful drug development would provide a single medicine that is curative, transmission blocking and prophylactic.

106 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

0 11
VeonGen Therapeutics GmbH VeonGen Therapeutics GmbH

Dedicated to develop the medicines of the future ViGeneron was founded in 2017 as a spin-off of the Ludwig-Maximilians-University (LMU) Munich. At ViGeneron we are dedicated to develop innovative gene therapies based on our two unique and proprietary technology platforms. ViGeneron will leverage its two technology platforms to address unmet medical needs with in-house gene therapy programs for selected retinal disorders. Together with partners we will exploit our ViGeneron technologies for additional indications. Gene Therapy, Inherited Retinal Disorders, and AAV vector

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

0 9
Synthorx Inc Synthorx Inc

Synthorx, Inc. is a biotechnology company focused on prolonging and improving the lives of people with cancer and autoimmune disorders. Synthorx’s proprietary, first-of-its-kind Expanded Genetic Alphabet platform technology expands the genetic code by adding a new DNA base pair and is designed to create optimized biologics, referred to as Synthorins. A Synthorin is a protein optimized through incorporation of novel amino acids encoded by the new DNA base pair that enables site-specific modifications, which enhance the pharmacological properties of these therapeutics. The company’s lead product candidate, THOR-707, a variant of IL-2, is in development in multiple tumor types as a …

22 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

2 5
REGENXBIO REGENXBIO

Seeking to improve lives through the curative potential of gene therapy. REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with …

14 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology SaaS

2 387
Pepkon Pepkon

PepKon is a french biotechnology company founded in 2022. The company develops first-in-class peptides for the treatment of incurable or poor prognosis cancers. These drug-candidates come from over a decade of academic research, resulting in seven scientific publications and two patent families

134 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

13 8
Generare Generare

Natural molecule discovery, industrialized Natural products have contributed more than 500 molecules to pharmaceuticals. However, conventional methods for discovering new natural products are increasingly ineffective. Generare has developed a revolutionary platform that identifies and expresses a wide range of naturally occurring secondary metabolites, selected by millions of years of bacterial evolution. This platform allows us to reintroduce these lead molecules into clinical pipelines, reopening a validated avenue for therapeutic innovation. genomics, synbio, and microbiology

98 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

8 23
Zionexa Zionexa

Targeted imaging and therapies Zionexa is an international and innovative company developing and commercializing molecular imaging solutions, in-vivo biomarkers for targeted therapies in oncology, to improve patients’ pathway and bring them a better quality of life. Molecular Imaging, Oncology, Targeted therapies, CDx, Radiopharmaceuticals, and Biomarkers

60 similar entities Type: Startup Activities: biotech deeptech

0 6
Elektrofi Elektrofi

Formulating the Future of BiologicsTM Elektrofi is a biopharmaceutical formulation technology company that is revolutionizing the delivery of biologic therapies by giving patients the ability to control how they want to receive and benefit from life-changing medicines. Our breakthrough hyper concentration microparticle technology platform, HyperconTM, resolves the limitations associated with intravenously delivered biologic therapies by enabling convenient at-home subcutaneous self-administration. With a focus on monoclonal antibodies, therapeutic proteins, and other large molecule drugs, we create, develop, and commercialize subcutaneous biologic therapies in collaboration with strategic partners. We believe a patient-centered healthcare approach can lead to a healthier world. We are …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

3 96
ELSALYS BIOTECH ELSALYS BIOTECH

Innovative medicines to address haemato-oncology related life-threatening and rare diseases ElsaLys Biotech is a specialty pharmaceutical company, part of the Mediolanum Farmaceutici Spa group, focused on innovative medicines to address haemato-oncology related life-threatening and rare diseases. Following strategic acquisitions and targeted developments, ElsaLys is establishing an immunotherapeutic portfolio focused on niche specialty pharmaceuticals to answer unmet medical needs. Our commitment is to offer essential drugs meeting Public Health needs. Founded in 2013, ElsaLys Biotech is located in the heart of the European cluster Lyon Biopole, in Lyon, France. Anticorps thérapeutiques, Anticorps monoclonaux, Therapeutic antibodies, Monoclonal antibodies, ophtalmologie, immune microenvironment, vascular …

56 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

7 1
Genbiotech Genbiotech

Bringing People & Ressources Together The creation of Genbiotech, a spinoff of the Laboratoires Genévrier results of 15 years of strategic involvement in biotechnological research with one goal: to improve the quality of life of patients in the field of rheumatology, dermatology and aesthetic. We believe that tomorrow medicine needs to be dedicated and targeted to patients. We aim to improve existing treatments by using non invasive processes allowing local and sustained administration of biological and active molécules. The company, incepted in 1998, has currently a staff of 11 people and is located in Sophia Antipolis (South of France). For …

54 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

1 8
ManRos Therapeutics ManRos Therapeutics

From Sea to Pharmacy ManRos Therapeutics is a biotech company identifying, optimizing and characterizing innovative, low molecular weight kinase inhibitors for the treatment of cystic fibrosis. ManRos was founded in 2007 and is led by Dr Laurent MEIJER, Chairman and CSO, former distinguished Director of Research at the CNRS, and Dr Philippe de Lavenne, CEO, former Vice-President at Actelion Pharmaceuticals. For 40 years, Dr Meijer dedicated his research to the study of protein kinases and their inhibitors, mostly at the CNRS. Drug Development, Cystic Fibrosis, and Biotechnology

58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

2 5
Ecrins Therapeutics Ecrins Therapeutics

Ecrins Therapeutics is a biotechnology company which focuses on the discovery and development of novel anti-cancer compounds from the preclinical phase to phase II clinical proof of concept. In addition to the drug discovery, Ecrins Therapeutics provides a range of products and services for the benefit of our customers in biotechnology companies, universities, public research institutions and in the pharmaceutical industry. The mission of the commercial division of Ecrins Therapeutics is to help medical chemists and drug hunters to discover, characterize and advance their lead compounds through the drug development process. Visit http://ecrins-therapeutics-services.com/ for more information. Our research and production …

44 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

3 1
KCAS Bio - Lyon KCAS Bio - Lyon

Science Accelerated KCAS Bio - Lyon (Active Biomarkers) operates as a bioanalytical laboratory based in Lyon, France and headquartered in Olathe, Kansas, USA. We offer comprehensive service solutions for the development of both large and small molecules, with extensive capabilities and expertise in pharmacokinetics, immunogenicity, soluble and cellular biomarker analysis for clinical trials. Operating in state-of-the-art BSL2 facilities, our company is GLP certified and ISO 9001:2015 certified, with a unique track-record in the development, validation, and implementation of analytical methods. Our expert team has supported hundreds of studies in multiple therapeutic areas: oncology, infectious diseases, inflammatory pathologies, and neurodegenerative diseases. …

54 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology Data Analytics

2 31
Mablink Bioscience Mablink Bioscience

Transforming cancer immunotherapy with next generation ADCs Mablink Bioscience is a French biotechnology company that is actively involved in the fight against cancer by bringing disruptive therapeutic solutions. With its Antibody-Drug Conjugates (ADC) masking technology, Mablink Bioscience aims to dramatically improve the efficiency of ADC therapies and accelerate the development of new treatments. Based in Lyon, where it is developing an unprecedented innovation center, Mablink currently has around 30 employees with diverse backgrounds. biotechnology, drug development, drug discovery, oncology, and R&D

68 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

15 35